Statins inhibit Aβ-neurotoxicity in vitro and Aβ-induced vasoconstriction and inflammation in rat aortae

Atherosclerosis

Volumn 161, Issue 2, 2002, Pages 293-299

  Paris, Daniel ^a   Townsend, Kirk P ^a   Humphrey, James ^a   Obregon, Demian F ^a   Yokota, Kiyoko ^a   Mullan, Michael ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

A ; Alzheimer's disease; Eicosanoids; Endothelin 1; Inflammation; Interleukin; Phospholipase A2; Prostaglandin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; COMPACTIN; ENDOTHELIN 1; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; MEVALONIC ACID; MEVINOLIN; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

ALZHEIMER DISEASE; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; INFLAMMATION; MALE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RING;

ALPROSTADIL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; CELLS, CULTURED; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; LOVASTATIN; MALE; MODELS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; VASCULITIS; VASOCONSTRICTION;

EID: 0036121232     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00660-8     Document Type: Article

References (30)

1. The Alzheimer diseases
2. Brain microvascular changes in Alzheimer's disease and other dementias
3. Microvascular pathology and vascular basement membrane components in Alzheimer's disease
4. The role of cerebral ischemia in Alzheimer's disease
5. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT
6. Early diagnosis of Alzheimer's disease by neuroimaging methods
7. Regional cerebral blood flow single-photon emission tomography with 99mTc-HMPAO and the acetazolamide test in the evaluation of vascular and Alzheimer's dementia
8. Preclinical prediction of Alzheimer's disease using SPECT
9. Vascular risk factors for Alzheimer's disease: An epidemiologic perspective
10. Arteriosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study
11. Diabetes mellitus and the risk of dementia: The Rotterdam Study
12. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam Study
13. Dietary fat intake and the risk of incident dementia in the Rotterdam Study
14. 15-Year longitudinal study of blood pressure and dementia
15. Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease?
16. Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway
17. Cholesterol modulates vascular reactivity to endothelin-1 by stimulating a pro-inflammatory pathway
18. Native nicotinic acetylcholine receptors in human Imr32 neuroblastoma cells: Functional, immunological and pharmacological properties
19. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase
20. Anti-amyloidogenic activity of tetracyclines: Studies in vitro
21. Stimulation of bone formation in vitro and in rodents by statins
22. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac
23. Statins and the risk of dementia
24. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
25. The role of cholesterol in the biosynthesis of beta-amyloid
26. Intraneuronal β-amyloid immunoreactivity in the CNS
27. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-conenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin
28. Tissue selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3 hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
29. HMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, trk, and morphological differentiation with fatal outcome in PC12 cells
30. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibition